Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05321147
Other study ID # IPH4102-102
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 17, 2022
Est. completion date February 8, 2024

Study information

Verified date March 2024
Source Innate Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-center phase Ib study, which evaluates the safety and efficacy of lacutamab monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2.


Description:

This is an open-label, single-arm multicenter study. Eligible patients will be enrolled and will receive fixed dose of 750mg Lacutamab as a 1-hour IV infusion.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 8, 2024
Est. primary completion date November 19, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Any subtype of PTCL; 2. Patients should have received at least one prior line of systemic therapy; 3. Patient with documented refractory, relapsed, or progressive disease. Patients must receive at least 2 cycles of prior line of systemic therapy (N-1). The patients who have withdrawn from prior (N-1) line of systemic therapy due to unacceptable toxicity must have received at least 2 cycles of prior (N-2) line of therapy; 4. KIR3DL2 expression (= 1%) based on central evaluation by IHC of either a newly acquired biopsy (preferred) or a tissue sample collected from a historical lymph node biopsy; 5. Presence of at least 1 target lesion on PET/CT scan at screening; 6. Male or Female, at least 18 years of age; 7. ECOG performance status = 2; 8. The patient must have a minimum wash-out period of 3 weeks between the last dose of prior line of systemic therapy and first dose of lacutamab; 9. Patients should have recovered from clinically relevant adverse events related to prior therapy to = grade 1. Certain toxicities will not be considered in this category (e.g., Grade 2 alopecia, peripheral neuropathy and/or endocrine end-organ failure being adequately managed by hormone replacement therapy); 10. Adequate baseline laboratory data: Hematology: - Hemoglobin >9 g/dL - Absolute neutrophil count (ANC) =1,000/µL, - Platelets =50,000/µL, Biochemistry: - Bilirubin =1.5 X upper limit of normal (ULN) or =3 X ULN for patients with Gilbert's disease, - Serum creatinine =1.5 X ULN, - Creatinine clearance =30 mL/min, assessed using the Cockcroft & Gault formula - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =3 X ULN; 11. Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12 months and capable to become pregnant. They must have a negative serum beta-HCG pregnancy test result within seven days before start of treatment; 12. Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug 13. Signed informed consent form prior to any protocol-specific procedure being performed. Exclusion Criteria: 1. Treatment with > 8 lines of systemic therapies prior to enrollment. Consolidation therapy including stem cell transplant is not considered a line of therapy; 2. Patients having a life expectancy of less than 3 months; 3. Receipt of live vaccines within 4 weeks prior to treatment; 4. Known central nervous system (CNS) lymphoma involvement; 5. Prior treatment with lacutamab; 6. Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study; 7. Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents or immunotherapy; 8. Autologous stem cell transplantation less than 3 months prior to enrollment; 9. Prior allogenic transplantation; 10. Patients who have undergone major surgery = 4 weeks prior to study entry; 11. Patients with known NCI-CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection; 12. Patients who have active Hepatitis B or C virus infection confirmed by PCR; 13. Patients known or tested positive for human immunodeficiency virus (HIV); 14. Patients with a history of other malignancies during the past three years apart from the disease subject of this study. The following are exempt from the three-year limit: non_melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer, biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or cervical carcinoma in situ. 15. Pregnant or breastfeeding women; 16. Patients with congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria; 17. Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol; 18. Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.

Study Design


Intervention

Biological:
lacutamab
Patients will receive a fixed dose of 750mg as 1-hour IV infusion

Locations

Country Name City State
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of Chungnam National University Hospital Daejeon
Korea, Republic of Seoul National University Bundang Hospital Gyeonggi-do
Korea, Republic of Gachon University Gil Medical Center Incheon
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of Severance Hospital Yonsei University Health System Seoul
Korea, Republic of The Catholic University of Korea, Yeouido St. Mary's Hospital Seoul
United States University of Maryland Baltimore Maryland
United States University of Alabama at Birmingham- O'Neal Comprehensive Cancer Center Birmingham Alabama
United States Medical University of South Carolina - Health Hollings Cancer Center Charleston South Carolina
United States Goshen Health- Goshen Hospital Goshen Indiana
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Indiana University School of Medicine Indianapolis Indiana
United States University of Iowa Iowa City Iowa
United States Memorial Sloan Kettering Cancer Center- David H. Koch Center for Cancer Care New York New York
United States University of California at Irvine - Chao Family Comprehensive Cancer Center Orange California
United States Allegheny Health Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Innate Pharma

Countries where clinical trial is conducted

United States,  Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of adverse events (AEs) Frequency and intensity of adverse events and serious adverse events. From consent is obtained until EOT visit (28 days after the last administration of study drug lacutamab)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04526834 - Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04390737 - Evaluate the Safety and Clinical Activity of HH2853 Phase 1/Phase 2
Recruiting NCT05559008 - A Umbrella Study in R/R PTCL Guided by Molecular Subtypes Phase 1/Phase 2
Recruiting NCT06083701 - Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study Phase 1/Phase 2
Not yet recruiting NCT02856997 - Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04083495 - CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma Phase 2
Not yet recruiting NCT05979792 - Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma Early Phase 1
Recruiting NCT04984837 - Study of Lacutamab in Peripheral T-cell Lymphoma Phase 2
Recruiting NCT06072131 - To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Phase 3
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Terminated NCT03947255 - A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma Phase 2
Recruiting NCT04028440 - γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Early Phase 1
Not yet recruiting NCT05923502 - (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
Recruiting NCT05377827 - Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies Phase 1
Recruiting NCT05883449 - Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL Phase 2
Active, not recruiting NCT03586999 - Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Phase 1/Phase 2
Recruiting NCT04489264 - The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
Recruiting NCT06151106 - Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma Phase 2
Recruiting NCT02753543 - Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma Phase 2
Not yet recruiting NCT06089941 - Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas